299. Roznovjak D, et al. (2023) JCO Oncol Pract, 19: e794. 300. Wiese D, et al. (2023) J Natl Cancer Inst, 115: 337. 301. Poulson MR, et al. (2022) J Thorac Cardiovasc Surg, 163: 1920. 302. Nelson NG, et al. (2023) Cancers (Basel), 15. 303. The Community Guide. TFFRS: Patient Navigation Services to Increase Cancer Screenings | The Community Guide. Accessed: July 5, 2023. Available from: https:// www.thecommunityguide.org/pages/tffrs-cancerscreening-patient-navigation-services-to-increase-breastcervical-colorectal-cancer-screenings.html. 304. Community Preventive Services Task Force. 2022 Annual Report to Congress. Accessed: July 5, 2023. Available from: https://www.thecommunityguide.org/media/2023/ pdf/2022-annual-report-congress-508.pdf. 305. Champion VL, et al. (2023) JAMA Netw Open, 6: e2311004. 306. Pretsch PK, et al. (2023) Lancet Public Health, 8: e411. 307. Lau J, et al. (2022) Prev Med, 164: 107343. 308. Sharma KP, et al. (2022) Prev Med Rep, 29: 101904. 309. National Cancer Institute. National Cancer Plan. Accessed: July 5, 2023. Available from: https:// nationalcancerplan.cancer.gov/national-cancer-plan.pdf. 310. Xu H, et al. (2023) Clin Gastroenterol Hepatol, 21: 337. 311. Mikhael PG, et al. (2023) J Clin Oncol, 41: 2191. 312. Levy I, et al. (2022) Am J Gastroenterol, 117: 1871. 313. Shaukat A, et al. (2022) Gastroenterology, 163: 732. 314. National Cancer Institute. Artificial Intelligence. Accessed: June 30, 2022. Available from: https:// www.cancer.gov/research/areas/diagnosis/artificialintelligence. 315. U.S. Food and Drug Administration. Artificial Intelligence and Machine Learning (AI/ML)-Enabled Medical Devices. Accessed: July 5, 2023. Available from: https://www.fda.gov/medical-devices/software-medicaldevice-samd/artificial-intelligence-and-machinelearning-aiml-enabled-medical-devices. 316. Iqbal MJ, et al. (2021) Cancer Cell Int, 21: 270. 317. Connal S, et al. (2023) J Transl Med, 21: 118. 318. Christodoulou E, et al. (2023) NPJ Precis Oncol, 7: 21. 319. Doubeni CA, et al. (2023) Am Fam Physician, 107: 224. 320. Doubeni CA, et al. (2022) Cancer, 128 Suppl 4: 883. 321. Oxford Cancer. SYMPLIFY. Accessed: July 5, 2023. Available from: https://www.cancer.ox.ac.uk/research/ projects/symplify. 322. Sasieni P, et al. (2023) Br J Cancer, 129: 72. 323. National Cancer Institute. Liquid Biopsy Consortium. Accessed: July 5, 2023. Available from: https://prevention. cancer.gov/major-programs/liquid-biopsy-consortium. 324. National Cancer Institute. Cancer Screening Research Network/MultiCancer Early Detection Evaluation. Accessed: July 5, 2023. Available from: https://deainfo. nci.nih.gov/advisory/joint/0622/Castle.pdf. 325. Cronin KA, et al. (2022) Cancer, 128: 4251. 326. Arfe A, et al. (2023) J Natl Cancer Inst, 115:917 327. Shadbolt C, et al. (2023) JAMA Netw Open, 6: e2250996. 328. Kingwell K (2022) Nat Rev Drug Discov, 21: 702. 329. Li A, et al. (2020) Cancer, 126: 4838. 330. Quantum Leap Healthcare Collaborative. The I-SPY Trials. Accessed: July 31, 2023. Available from: https:// www.ispytrials.org/. 331. Wang H, et al. (2019) Curr Breast Cancer Rep, 11: 303. 332. IQVIA. Global Oncology Trends 2023. Accessed: July 5, 2023. Available from: https://www.iqvia.com/insights/ the-iqvia-institute/reports/global-oncology-trends-2023. 333. Subbiah V (2023) Nat Med, 29: 49. 334. In: Bibbins-Domingo K, Helman A, editors. Improving Representation in Clinical Trials and Research: Building Research Equity for Women and Underrepresented Groups. Washington (DC)2022. 335. Varma T, et al. (2023) BMJ Medicine, 2: e000395. 336. Green AK, et al. (2022) JAMA Oncol, 8: 1786. 337. Saez-Ibanez AR, et al. (2022) Nat Rev Drug Discov, 21: 870. 338. Mulligan KM, et al. (2023) Arch Dermatol Res, 315: 1033. 339. U.S. Food and Drug Administration. Drug Trials Snapshots Summary Report 2022. Accessed: July 31, 2023. Available from: https://www.fda.gov/ media/168662/download. 340. Kahn JM, et al. (2022) Cancer, 128: 216. 341. U.S. Food and Drug Administration. Diversity Plans to Improve Enrollment of Participants From Underrepresented Racial and Ethnic Populations in Clinical Trials; Draft Guidance for Industry; Availability. Accessed: July 5, 2023. Available from: https://www. fda.gov/regulatory-information/search-fda-guidancedocuments/diversity-plans-improve-enrollmentparticipants-underrepresented-racial-and-ethnicpopulations. AACR Cancer Progress Report 2023 References 174
RkJQdWJsaXNoZXIy NTkzMzk=